Daiichi Sankyo Company (4568) 주식 개요
다이이찌산쿄는 일본, 북미, 유럽 및 전 세계에서 의약품을 제조 및 판매하는 회사입니다. 자세히 보기
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Daiichi Sankyo Company, Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | JP¥2,729.00 |
| 52주 최고가 | JP¥4,178.00 |
| 52주 최저가 | JP¥2,390.00 |
| 베타 | -0.18 |
| 1개월 변동 | 1.94% |
| 3개월 변동 | 6.02% |
| 1년 변동 | -25.76% |
| 3년 변동 | -34.40% |
| 5년 변동 | 8.47% |
| IPO 이후 변동 | 253.65% |
최근 뉴스 및 업데이트
분석 기사 • Aug 10
Earnings Troubles May Signal Larger Issues for Daiichi Sankyo Company (TSE:4568) Shareholders
The market wasn't impressed with the soft earnings from Daiichi Sankyo Company, Limited ( TSE:4568 ) recently. We did...
내러티브 업데이트 • Jul 31
4568: Oncology Approvals And Guidance Upgrades Will Drive Future Upside
Analysts have trimmed their price target for Daiichi Sankyo Company to around ¥4,146 from roughly ¥4,235, reflecting slightly softer assumptions for revenue growth, profit margins and future P/E multiples. What’s in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.Recent updates
분석 기사 • Aug 10
Earnings Troubles May Signal Larger Issues for Daiichi Sankyo Company (TSE:4568) Shareholders
The market wasn't impressed with the soft earnings from Daiichi Sankyo Company, Limited ( TSE:4568 ) recently. We did...내러티브 업데이트 • Jul 31
4568: Oncology Approvals And Guidance Upgrades Will Drive Future Upside
Analysts have trimmed their price target for Daiichi Sankyo Company to around ¥4,146 from roughly ¥4,235, reflecting slightly softer assumptions for revenue growth, profit margins and future P/E multiples. What’s in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.
내러티브 업데이트 • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
내러티브 업데이트 • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.내러티브 업데이트 • Jun 16
4568: Oncology Biomarker Advances And Pipeline Approvals Will Drive Future Upside
Analysts have reduced their fair value estimate for Daiichi Sankyo Company from ¥4,736.88 to ¥4,234.71, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Leica Biosystems expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and AI powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non small cell lung cancer, building on AstraZeneca’s computational pathology algorithm and Leica’s digital pathology platform for research use only.내러티브 업데이트 • Jun 01
4568: Oncology Pipeline Progress And Measured Outlook Will Support Future Market Rating
Analysts have trimmed their price target for Daiichi Sankyo Company from about ¥3,065 to around ¥2,846. This reflects updated assumptions for slightly lower revenue growth, a reduced profit margin, a modestly higher discount rate, and a small adjustment to future P/E expectations.분석 기사 • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...내러티브 업데이트 • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.내러티브 업데이트 • Apr 23
4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating
Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).내러티브 업데이트 • Apr 08
4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential
Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).내러티브 업데이트 • Mar 25
4568: Oncology Pipeline Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).내러티브 업데이트 • Mar 11
4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).내러티브 업데이트 • Feb 25
4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).내러티브 업데이트 • Feb 10
4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating
Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).분석 기사 • Feb 08
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...분석 기사 • Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...분석 기사 • Feb 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...내러티브 업데이트 • Jan 26
4568: Oncology Approvals And Trials Will Drive Future Upside Potential
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.분석 기사 • Jan 23
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...내러티브 업데이트 • Jan 12
4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).분석 기사 • Jan 09
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...내러티브 업데이트 • Dec 27
4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside
Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).분석 기사 • Dec 25
Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...내러티브 업데이트 • Dec 13
4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside
Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.분석 기사 • Dec 11
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...내러티브 업데이트 • Nov 25
4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares
Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.분석 기사 • Nov 04
Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...내러티브 업데이트 • Oct 22
Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks
Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.내러티브 업데이트 • Oct 08
Global Aging And ADC Pipelines Will Expand Oncology Markets
Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.분석 기사 • Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...분석 기사 • Sep 05
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...내러티브 업데이트 • Sep 04
Global Aging And ADC Pipelines Will Expand Oncology Markets
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.분석 기사 • Aug 22
Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...주주 수익률
| 4568 | JP Pharmaceuticals | JP 시장 | |
|---|---|---|---|
| 7D | -0.8% | 0.09% | 2.9% |
| 1Y | -25.8% | 13.5% | 34.0% |
수익률 대 산업: 4568은 지난 1년 동안 13.5%의 수익을 기록한 JP Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: 4568은 지난 1년 동안 34%를 기록한 JP 시장보다 저조한 성과를 냈습니다.
주가 변동성
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.2% |
안정적인 주가: 4568는 지난 3개월 동안 JP 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: 4568의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1899 | 20,171 | Hiroyuki Okuzawa | www.daiichisankyo.com |
다이이찌산쿄는 일본, 북미, 유럽 및 전 세계에서 의약품을 제조 및 판매하고 있습니다. 이 회사는 HER2 양성 및 저 유방암, HER2 양성 위암 또는 위식도 접합부 선암, HER2 양성 고형 종양 환자 치료를 위한 인핸서투(Enhertu)를 제공합니다; 콜로니 자극 인자 1 수용체, KIT 원시 종양 유전자 수용체 티로신 키나제 및 내부 탠덤 중복 돌연변이를 보유한 FMS 유사 티로신 키나제 3을 표적으로 하는 경구용 저분자 치료제 투랄리오, 급성 골수성 백혈병 성인 환자 치료를 위한 FLT3 억제제 반플라타, 철 결핍 치료를 위한 페릭 카르복시말토스 주사제 인젝타페르. 또한 직접 응고 인자 억제제인 리지아나와 사바사, 항고혈압제인 민네브로, 올메텍, 올메텍 플러스, 레잘타스, 세비카, 세비카 HCT, 콜레스테롤 저하 경구 치료제인 나일렘도, 콜레스테롤 감소를 위한 벰페도산과 에제티미브의 고정 용량 복합제인 누스텐디, 항혈소판제인 이피엔트 등을 공급하고 있습니다.
Daiichi Sankyo Company, Limited 기초 지표 요약
| 4568 기초 통계 | |
|---|---|
| 시가총액 | JP¥4.97t |
| 순이익 (TTM) | JP¥243.01b |
| 매출 (TTM) | JP¥2.22t |
20.4x
주가수익비율(P/E)2.2x
주가매출비율(P/S)4568는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| 4568 손익계산서 (TTM) | |
|---|---|
| 매출 | JP¥2.22t |
| 매출원가 | JP¥700.99b |
| 총이익 | JP¥1.52t |
| 기타 비용 | JP¥1.28t |
| 순이익 | JP¥243.01b |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 133.49 |
| 총이익률 | 68.47% |
| 순이익률 | 10.93% |
| 부채/자본 비율 | 29.4% |
4568의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Daiichi Sankyo Company 배당 일정 | |
|---|---|
| 배당락일 | Sep 29 2026 |
| 배당 지급일 | Dec 10 2026 |
| 배당락일까지 남은 일수 | 45 days |
| 배당 지급일까지 남은 일수 | 117 days |
4568는 안정적으로 배당을 지급합니까?
4568 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/14 05:58 |
| 종가 | 2026/08/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Daiichi Sankyo Company, Limited는 28명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |